docetaxel + pirarubicin + ifosfamide

This is a combination chemotherapy regimen consisting of three agents: docetaxel, pirarubicin, and ifosfamide. **Docetaxel** is a taxane antineoplastic agent that promotes the assembly and stabilization of microtubules by binding to the β-subunit of tubulin, thereby inhibiting their depolymerization. This disrupts normal mitotic and interphase cellular functions, leading to cell cycle arrest and apoptosis[4]. **Pirarubicin** is an anthracycline antibiotic structurally related to doxorubicin; it acts primarily as a DNA intercalator and topoisomerase II inhibitor, causing DNA damage and inhibition of replication (not directly cited in search results but well established). **Ifosfamide** is an alkylating agent that requires hepatic activation; its active metabolites alkylate DNA at the N7 position of guanine, resulting in cross-linking that inhibits DNA replication and leads to cell death[6][8]. This combination has been studied for use in advanced cancers such as soft tissue sarcoma. The rationale for combining these drugs lies in their non-overlapping mechanisms of action—microtubule stabilization (docetaxel), DNA intercalation/topoisomerase inhibition (pirarubicin), and DNA alkylation/cross-linking (ifosfamide)—and partially non-overlapping toxicity profiles[1][2]. The regimen aims to maximize anti-tumor efficacy while managing cumulative toxicities.

Brand names

Pirarubicin (no widely used brand name, often referred to by generic)

Other names

None